WallStreetZenWallStreetZen

NASDAQ: ADVM
Adverum Biotechnologies Inc Stock Forecast, Predictions & Price Target

Analyst price target for ADVM

Based on 5 analysts offering 12 month price targets for Adverum Biotechnologies Inc.
Min Forecast
$20.00+154.13%
Avg Forecast
$34.40+337.1%
Max Forecast
$60.00+662.39%

Should I buy or sell ADVM stock?

Based on 5 analysts offering ratings for Adverum Biotechnologies Inc.
Strong Buy
Strong Buy
3 analysts 60%
Buy
1 analysts 20%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ADVM stock forecasts and price targets.

ADVM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-15
lockedlocked$00.00+00.00%2024-05-10
lockedlocked$00.00+00.00%2024-04-29
lockedlocked$00.00+00.00%2024-03-19
lockedlocked$00.00+00.00%2024-03-19

1 of 1

Forecast return on equity

Is ADVM forecast to generate an efficient return?
Company
-80.05%
Industry
76.1%
Market
79%
ADVM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ADVM forecast to generate an efficient return on assets?
Company
-54.48%
Industry
30.96%
ADVM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ADVM earnings per share forecast

What is ADVM's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$5.42
Avg 2 year Forecast
-$5.55
Avg 3 year Forecast
-$6.44

ADVM revenue forecast

What is ADVM's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.7M
Avg 2 year Forecast
$1.6M
Avg 3 year Forecast
$1.5M

ADVM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADVM$7.87$34.40+337.10%Strong Buy
TELO$5.51N/AN/A
ZURA$3.74$23.50+528.34%Strong Buy
DRTS$2.33$8.00+243.35%Strong Buy
ABOS$2.70$15.00+455.56%Buy

Adverum Biotechnologies Stock Forecast FAQ

Is Adverum Biotechnologies Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ADVM) stock is to Strong Buy ADVM stock.

Out of 5 analysts, 3 (60%) are recommending ADVM as a Strong Buy, 1 (20%) are recommending ADVM as a Buy, 1 (20%) are recommending ADVM as a Hold, 0 (0%) are recommending ADVM as a Sell, and 0 (0%) are recommending ADVM as a Strong Sell.

If you're new to stock investing, here's how to buy Adverum Biotechnologies stock.

What is ADVM's earnings growth forecast for 2024-2026?

(NASDAQ: ADVM) Adverum Biotechnologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.61%.

Adverum Biotechnologies's earnings in 2024 is -$112,896,000.On average, 5 Wall Street analysts forecast ADVM's earnings for 2024 to be -$112,543,641, with the lowest ADVM earnings forecast at -$124,748,669, and the highest ADVM earnings forecast at -$101,708,565. On average, 4 Wall Street analysts forecast ADVM's earnings for 2025 to be -$115,148,625, with the lowest ADVM earnings forecast at -$120,182,162, and the highest ADVM earnings forecast at -$101,708,565.

In 2026, ADVM is forecast to generate -$133,674,114 in earnings, with the lowest earnings forecast at -$133,674,114 and the highest earnings forecast at -$133,674,114.

What is ADVM's revenue growth forecast for 2024-2026?

(NASDAQ: ADVM) Adverum Biotechnologies's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.

Adverum Biotechnologies's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ADVM's revenue for 2024 to be $34,663,940, with the lowest ADVM revenue forecast at $34,663,940, and the highest ADVM revenue forecast at $34,663,940. On average, 1 Wall Street analysts forecast ADVM's revenue for 2025 to be $33,003,392, with the lowest ADVM revenue forecast at $33,003,392, and the highest ADVM revenue forecast at $33,003,392.

In 2026, ADVM is forecast to generate $31,342,844 in revenue, with the lowest revenue forecast at $31,342,844 and the highest revenue forecast at $31,342,844.

What is ADVM's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ADVM) forecast ROA is -54.48%, which is lower than the forecast US Biotechnology industry average of 30.96%.

What is ADVM's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ADVM price target, the average ADVM price target is $34.40, with the highest ADVM stock price forecast at $60.00 and the lowest ADVM stock price forecast at $20.00.

On average, Wall Street analysts predict that Adverum Biotechnologies's share price could reach $34.40 by May 15, 2025. The average Adverum Biotechnologies stock price prediction forecasts a potential upside of 337.1% from the current ADVM share price of $7.87.

What is ADVM's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: ADVM) Adverum Biotechnologies's current Earnings Per Share (EPS) is -$10.20. On average, analysts forecast that ADVM's EPS will be -$5.42 for 2024, with the lowest EPS forecast at -$6.01, and the highest EPS forecast at -$4.90. On average, analysts forecast that ADVM's EPS will be -$5.55 for 2025, with the lowest EPS forecast at -$5.79, and the highest EPS forecast at -$4.90. In 2026, ADVM's EPS is forecast to hit -$6.44 (min: -$6.44, max: -$6.44).

What is ADVM's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ADVM) forecast ROE is -80.05%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.